Odense C

• Bomedemstat vs Hydroxyurea for Essential Thrombocythemia Recruiting
  2023-505232-36-00 5 2024-11-15 Essential thrombocythemia
• A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc … Recruiting
  2024-511319-91-00 5 2024-10-23 Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
• New Beacon Recruiting
  2024-518419-20-00 4 2024-10-23 BRAF V600E mutated colorectal cancer
• Targeting mTOR with everolimus and/or physical training for preventing postmenopausal bone loss and accelerated skeletal aging. The RapaLoad … Recruiting
  2023-508093-28-00 4 2024-10-20 Healthy
• Beneficial effects of Amiloride on progression of Chronic Kidney Disease: A-CKA Recruiting
  2022-500692-31-00 4 2024-10-10 Chronic kidney disease (CKD)
• Repairing Peri-Anal Fistulas with regenerative cell therapeutics (REP-PAF) Recruiting
  2022-502659-73-01 7 2024-10-09 Crypto-glandular perianal fistula
• FAST TRIAL Recruiting
  2024-515507-18-00 5 2024-10-09 Status epilepticus
• A Study to Evaluate ARV-393 in Adult Participants with Advanced Non-Hodgkin’s Lymphoma Recruiting
  2023-510136-36-00 1 2024-09-27 Advanced Non-Hodgkin’s Lymphoma
• A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting
  2023-508811-21-00 10 2024-09-25 Refractory Focal Onset Epilepsy
• Local Antibiotics for Women Undergoing Breast Reconstruction Surgery with Implants Recruiting
  2024-517672-38-00 5 2024-09-20 Infection
• A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10 … Recruiting
  2023-507353-15-00 5 2024-09-10 idiopathic pulmonary fibrosis (IPF)
• OPTIMAL DIURETIC THERAPIES FOR ACUTE HEART FAILURE WITH VOLUME OVERLOAD Recruiting
  2024-510633-17-00 5 2024-09-05 acute heart failure
• A Phase 2b Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-506704-14-00 4 2024-09-04 Moderately to Severely Active Crohn's Disease
• Self-administration of subcutaneous Elranatamab in the patients’ homes (ERICA) Recruiting
  2023-507876-30-00 4 2024-09-04 Multiple Myeloma
• Safety and efficacy of oral semaglutide in hyperglycaemic patients after renal transplantation Recruiting
  2023-504159-29-01 4 2024-09-03 Hyperglycaemia after renal transplantation
• Improving diagnostics in cervical dysplasia Recruiting
  2024-517151-12-00 6 2024-09-01 Patients are either or both HPV positive and has cervical cell changes
• A study to assess the efficacy and safety of OATD-01 for the treatment of active pulmonary sarcoidosis. Recruiting
  2023-506642-23-01 4 2024-08-28 Active Pulmonary Sarcoidosis
• PHASE II STUDY OF AZACITIDINE IN COMBINATION WITH LOW DOSE INTENSITY VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH INTEGRATION OF … Recruiting
  2023-510415-19-00 4 2024-08-28 Acute Myeloid Leukemia
• An ascending dose study to determine the safety and effect of antibodies against hepatitis B (The SAMBA Study) Recruiting
  2023-508444-22-01 1 2024-08-26 Chronic hepatitis B infection
• Palliation of Dyspnea and Cough using Morphine in patients with Fibrotic Interstitial Lung Disease Recruiting
  2023-503700-81-00 6 2024-08-23 Fibrotic Interstitial Lung Disease
• Short course antibiotic treatment of Gram-negative bacteremia: A multicenter, randomized, non-blinded, non-inferiority interventional study Recruiting
  2024-514900-16-00 6 2024-07-25 Gram-negative Bacteremia
• HEMODIALYSIS AND ANTIBIOTIC PROPHYLAXIS Recruiting
  2024-515001-26-00 6 2024-07-25 Blood poisoning in patients with renal failure treated with hemodialys
• A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt … Recruiting
  2023-507684-19-00 5 2024-07-24 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
• Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting
  2023-504962-52-00 5 2024-07-10 Triple negative breast cancer.

Showing 169–192 of 467 trials